Antibody Therapy Market to Reach USD 824.0 Billion by 2033, Growing at a 13.4% CAGR

The global antibody therapy market is poised for substantial growth, projected to expand from USD 235 billion in 2023 to an impressive USD 824.0 billion by 2033. This represents a robust compound annual growth rate (CAGR) of 13.4% during the forecast period, driven by increasing adoption of monoclonal antibodies and significant advancements in healthcare research and development.

The market expansion is largely attributed to the growing demand for non-chemical, protein-based therapies, particularly for treating cell-based diseases and cancers. As patients increasingly seek alternative treatments to traditional chemotherapy, monoclonal antibody therapies are gaining popularity due to their targeted mechanisms and reduced side effects. This shift toward more effective, less toxic therapies is reshaping the landscape of oncology and immunology treatments.

Moreover, government investments in research and development, coupled with advancements in biotechnology, are propelling innovation in antibody therapies. The development of next-generation monoclonal antibodies and other antibody-based treatments is expected to address a wider range of diseases, further driving market growth. These therapeutic advancements are significantly enhancing treatment outcomes, contributing to the growing appeal of antibody therapies in both clinical and commercial settings.

Request a Sample Report Now to get Premium Insights: https://www.fmisamplereport.com/sample/rep-gb-14362

Key Takeaways:

• The global antibody therapy market is set to grow from USD 235 billion in 2023 to USD 824.0 billion by 2033, at a CAGR of 13.4%.
• The increasing preference for non-chemical, protein-based treatments, especially for cancer and cell-based diseases, is fueling market growth.
• Significant government spending on R&D and advancements in biotechnology are driving innovation in monoclonal antibody therapies.
• Next-generation antibody treatments are expected to expand therapeutic possibilities, further boosting market demand.

The research report on the antibody therapy market explains that progressive healthcare efforts, along with the higher government spending on research and development programs, have helped the antibody therapy market expand. Patients suffering from cell-based diseases along with cancer have started opting for the non-chemical, protein-based model that monoclonal antibody therapy provides.

The research and development programs that provide substantial data on higher effectiveness and lower side effects are likely to increase the operability of monoclonal antibody therapy, flourishing the sales of antibody therapies. Furthermore, the expansion of cancer-centric hospitals flourishes the demand for antibody therapy solutions.

The higher FDA approvals of advanced antibody therapy for Covid-19 cases boomed the market growth during the peak of the pandemic. Hence, the market flourished on a much higher CAGR of 18.2% between 2017 and 2022.

Competition Scenario

The fresh entry of significant players, on the other hand, may enhance competition. In addition, significant strategies in the competitive environment include expansion, acquisitions, partnerships, mergers, and acquisitions. In the approaching years, this market invests heavily in research and development to strengthen its position in the antibody industry and help them expand into big players.

Recent Market Developments

• In January 2022, TEZSPIRE (tezepelumab-ekko) was approved and made available by Amgen and AstraZeneca to treat severe asthma. The FDA’s approval of this medicine allows the corporation to expand its product line and generate significant income.
• In November 2020, Regeneron received an Emergency Use Authorization (EUA) from the US Food and Drug Administration for its COVID-19 antibody combination casirivimab and imdevimab. This approval has boosted its revenue generation and helped it gain considerable market share.

Major Contributors of the Antibody Therapy Market

• Bristol-Myers Squibb,
• GlaxoSmithKline plc,
• Takeda Pharmaceuticals,
• Eli Lilly and Company,
• Merck & Co, Inc.,
• Seagen, Johnson & Johnson,
• Novartis AG,
• Regeneron Pharmaceuticals,
• F. Hoffmann-La Roche Ltd.,
• Merck & Co, IncSeagen

Key Segments

By Type:

• Monoclonal Antibodies
  • Oncology, Autoimmune Disease
  • Infectious Disease
  • Other
• Antibody Drug Conjugates

By End User:

• Hospitals
• Specialty Centers
• Others

By Region:

• North America
• Latin America
• Europe
• Asia Pacific (APAC)
• Middle East & Africa (MEA)